Moderna, Inc. (MRNA) Presents at Jefferies London Healthcare Conference (Transcript)

Summary of Moderna, Inc. (NASDAQ:MRNA) Jefferies London Healthcare Conference Company Overview - Company: Moderna, Inc. (NASDAQ:MRNA) - Event: Jefferies London Healthcare Conference - Date: November 21, 2024 Key Points Industry Context - The biopharmaceutical industry, particularly the vaccine sector, is experiencing significant changes due to political rhetoric and administration shifts, which could impact market dynamics [2][3][4] Company Strategy and Focus - Moderna remains committed to executing its strategy in the vaccine space, emphasizing the importance of public health benefits of vaccines [8][9] - The company is focused on transparency in its clinical programs, having been the first to publish its Phase III study protocol during the COVID pandemic [5] COVID-19 Vaccine Market - Moderna is observing a stable and sizable market for COVID vaccines, with a recurring revenue model expected as uptake stabilizes [14][15] - The company anticipates a 10% decline in COVID vaccine sales for 2024 but expects to meet its revenue guidance [17] RSV Vaccine Development - The Advisory Committee on Immunization Practices (ACIP) is evaluating the revaccination frequency for RSV, which remains uncertain [18][21] - The eligible patient population for the RSV vaccine is estimated to be between 40 million and 50 million Americans, with a significant market opportunity [22][24] Upcoming Product Pipeline - Moderna has several key growth drivers, including: - CMV Vaccine: Currently in Phase III trials, with an interim analysis expected by the end of 2024 [27][30] - COVID-Flu Combination Vaccine: Anticipated to file for approval, leveraging existing antibody data for flu efficacy [48][49] - Merck Cancer Vaccine: Phase III study fully enrolled, with potential results expected in late 2025 [56][58] Financial Outlook - Moderna has $9 billion in cash and expects to launch 10 products over the next three years, contributing to revenue starting in 2026 [62][63] - The company aims for an incremental $3 billion in revenue by 2028, with a commitment to adjust operational expenses if revenue targets are not met [65][67] Market Concerns - There is skepticism in the market regarding Moderna's ability to reach $6 billion in revenue by 2028, with concerns about cash burn and profitability [60][66] Conclusion - Moderna is navigating a complex landscape in the biopharmaceutical industry, focusing on vaccine development and maintaining transparency while addressing market concerns about financial sustainability and growth potential [2][8][60]